We are initiating coverage of Annexin Pharmaceuticals, a world-leading biotech company within the Annexin A5 field. We see the early, clinical phases as risk-reduced and where they are in a good position to evaluate the full therapeutic potential of ANXV in several cardiovascular diseases.